Analysts See $-0.05 EPS for Ritter Pharmaceuticals, Inc. (RTTR)

February 14, 2018 - By Peter Erickson

 Analysts See $ 0.05 EPS for Ritter Pharmaceuticals, Inc. (RTTR)

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24 % from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29 % EPS growth. The stock increased 1.28% or $0.0038 during the last trading session, reaching $0.3018. About 199,997 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 14, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Coverage

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. The stock has “Buy” rating by Maxim Group on Thursday, April 14. The rating was maintained by Maxim Group on Wednesday, July 5 with “Hold”. Maxim Group maintained Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) on Friday, August 4 with “Hold” rating. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, October 25. As per Monday, October 23, the company rating was maintained by H.C. Wainwright. The stock of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has “Buy” rating given on Wednesday, January 4 by Rodman & Renshaw. The rating was maintained by Roth Capital with “Buy” on Monday, June 5. Chardan Capital Markets initiated the stock with “Buy” rating in Wednesday, December 2 report.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.94 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More notable recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: which released: “Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its …” on October 03, 2017, also with their article: “Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical …” published on January 29, 2018, published: “Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on …” on November 29, 2017. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) were released by: and their article: “Ritter Pharmaceuticals, Inc. Prices $23000000 Public Offering” published on September 29, 2017 as well as‘s news article titled: “Ritter Pharma Raises $23 million to Test Lactose Intolerance Treatment” with publication date: October 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: